L3VLUP
ProSign in

AGIO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AGIOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AGIO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAGIOVRTX
Q3 20209 holders, $371m31 holders, $21.9bn
Q4 20209 holders, $441m30 holders, $18.4bn
Q1 20219 holders, $483m31 holders, $15.4bn
Q2 20216 holders, $892m30 holders, $12.7bn
Q3 20216 holders, $283m35 holders, $10.1bn
Q4 20215 holders, $220m28 holders, $12.4bn
Q1 20227 holders, $203m23 holders, $16.1bn
Q2 20225 holders, $40m25 holders, $18.1bn
Q3 20227 holders, $198m22 holders, $18.4bn
Q4 20226 holders, $218m28 holders, $18.4bn
Q1 20235 holders, $186m26 holders, $21.4bn
Q2 20234 holders, $251m27 holders, $24.7bn
Q3 20234 holders, $205m33 holders, $24.3bn
Q4 20233 holders, $106m32 holders, $28.6bn
Q1 20245 holders, $180m31 holders, $29.8bn
Q2 202410 holders, $358m29 holders, $33.4bn
Q3 20246 holders, $332m27 holders, $33.5bn
Q4 20244 holders, $206m26 holders, $28.5bn
Q1 20253 holders, $181m21 holders, $35.4bn
Q2 20254 holders, $215m21 holders, $32.3bn
Q3 20253 holders, $250m22 holders, $25.9bn
Q4 20254 holders, $159m26 holders, $31.8bn
Q1 20265 holders, $306m25 holders, $31.8bn
Q2 20264 holders, $354m26 holders, $34.6bn
AGIO

Agios Pharmaceuticals Inc

Holders
5
Reported value
$306m
Buyers
14
Sellers
16

Breadth -2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 29 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AGIO (4)

Artisan Partners LP, Farallon Capital Management LLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →